Advanced

Clinical dosimetry in the treatment of bone tumors: old and new agents

Hindorf, Cecilia LU ; Flux, G. D.; Ibisch, C. and Bodere, F. Kraeber (2011) In Quarterly Journal of Nuclear Medicine and Molecular Imaging 55(2). p.198-204
Abstract
Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency (Sm-153-EDTMP and Sr-89-Cl-2) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries (Re-186-HEDP, Sn-117(m)-DTPA and Ra-223-Cl-2). The tissues at risk for the treatment are bone marrow and normal bone. A review of the methods applied for dosimetry for these tissues and for tumours is performed, including the calculation of S values (the absorbed dose per decay) and optimal procedures on how to obtain biodistribution data for each... (More)
Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency (Sm-153-EDTMP and Sr-89-Cl-2) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries (Re-186-HEDP, Sn-117(m)-DTPA and Ra-223-Cl-2). The tissues at risk for the treatment are bone marrow and normal bone. A review of the methods applied for dosimetry for these tissues and for tumours is performed, including the calculation of S values (the absorbed dose per decay) and optimal procedures on how to obtain biodistribution data for each radiopharmaceutical. The dosimetry data can be used to individualise and further improve the treatment for each patient. Dosimetry for radionuclide therapy of bone metastases is feasible and can be performed in a routine clinical practice. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Radiotherapy planning, Radionuclide therapy, Neoplasm metastasis, computer-assisted
in
Quarterly Journal of Nuclear Medicine and Molecular Imaging
volume
55
issue
2
pages
198 - 204
publisher
Edizioni Minerva Medica
external identifiers
  • wos:000291627700006
  • scopus:79957662849
ISSN
1824-4785
language
English
LU publication?
yes
id
dd83d3fc-3091-465c-967e-163f7548afe2 (old id 1984742)
date added to LUP
2011-07-01 09:13:14
date last changed
2017-01-01 05:33:13
@article{dd83d3fc-3091-465c-967e-163f7548afe2,
  abstract     = {Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency (Sm-153-EDTMP and Sr-89-Cl-2) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries (Re-186-HEDP, Sn-117(m)-DTPA and Ra-223-Cl-2). The tissues at risk for the treatment are bone marrow and normal bone. A review of the methods applied for dosimetry for these tissues and for tumours is performed, including the calculation of S values (the absorbed dose per decay) and optimal procedures on how to obtain biodistribution data for each radiopharmaceutical. The dosimetry data can be used to individualise and further improve the treatment for each patient. Dosimetry for radionuclide therapy of bone metastases is feasible and can be performed in a routine clinical practice.},
  author       = {Hindorf, Cecilia and Flux, G. D. and Ibisch, C. and Bodere, F. Kraeber},
  issn         = {1824-4785},
  keyword      = {Radiotherapy planning,Radionuclide therapy,Neoplasm metastasis,computer-assisted},
  language     = {eng},
  number       = {2},
  pages        = {198--204},
  publisher    = {Edizioni Minerva Medica},
  series       = {Quarterly Journal of Nuclear Medicine and Molecular Imaging},
  title        = {Clinical dosimetry in the treatment of bone tumors: old and new agents},
  volume       = {55},
  year         = {2011},
}